Drug Development Gene Therapy Cancer Treatment Neurology Animal Studies Neuroscience Innovative Treatments Immunotherapy Therapies Gene Therapy Trials Preclinical Models Drug Efficacy Autoimmune Diseases Vaccine Development Drug Approval Cancer Research Genetic Disorders Spinal Cord Injury Gene Editing Patient Outcomes Therapeutics Experimental Treatments Neurological Disorders Preclinical Studies Device Development Randomized Controlled Trials Phase 2 Trials Cardiovascular Diseases Patient Studies Phase 3 Studies Treatment Efficacy Data Annotation Dietary Interventions Phase 3 Trials FDA Approval Stem Cell Research Blood Tests Osteoarthritis Cancer Treatments Pain Management Obesity Treatments Transplantation Trials Protein Analysis Psychopharmacology Idiopathic Pulmonary Fibrosis Amputation Transform Trial Therapeutic Efficacy Prenatal Treatment Respiratory Failure Treatments Challenge Trials Estrogen Therapy Sensitivity and Specificity Infectious Diseases Research Institutions Heart Disease Drug Effectiveness Surgical Techniques Funding Challenges Organ Donation Animal Models Long-COVID Treatments Patient Care Evidence-Based Medicine Liver Disease Regulatory Compliance Study Findings Male Contraception Trials Allergies Groundbreaking Research Treatment Prediction Diabetes Medications Fatigue Disorders Inflammation Research Diabetes Parkinson's Drug Animal Testing Drug Repurposing Adaptive Treatments Stem Cell Therapy Weight-loss Studies PD-1 Immunotherapy Research Methodology Organ Transplantation Human Trials IVF Technology Desensitization Therapy Dietary Studies Neurosurgery Ovarian Function In Vitro Studies Cannabis Research Gender Bias Safety Testing Data Security Targeted Therapy Obesity Treatment Motor Neurone Disease Immunotherapy Research Neurodegenerative Diseases
Eli Lilly's $100 million anchor investment expanded the deal to fund early radiopharmaceutical programs.
